Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Radioligand Therapy Market: PSMA-Targeted Prostate Cancer Treatment Demand, Neuroendocrine Tumor Application Growth, and Alpha-Emitter Pipeline Adoption to Drive Exceptional Market Expansion Through 2035

The global Radioligand Therapy Market was valued at USD 3.3 billion in 2025 and is forecast to expand at an exceptional CAGR of 14.2%, reaching approximately USD 10.9 billion by 2035. This trajectory is underpinned by increasing clinical adoption of PSMA-targeted prostate cancer treatments, growing utilization in neuroendocrine tumor management, and continued advancement of alpha-emitting radionuclide candidates through late-stage development. The category comprises commercially marketed, regulatory-stage, and early clinical radioligand therapies applied across prostate cancer, neuroendocrine tumor, and an expanding set of solid tumor indications.

The market’s exceptional 14.2% CAGR reflects the transition of targeted radionuclide therapy from a specialized nuclear medicine technique into an established precision-oncology treatment class, generating demand from hospitals and comprehensive cancer centers that exceeds typical growth rates observed across the specialty pharmaceutical sector. Sustained clinical uptake of PSMA-directed prostate cancer regimens continues to support procurement volumes, while somatostatin receptor-targeted therapies for neuroendocrine tumors represent a distinct and growing demand channel among nuclear medicine providers. Coverage extending across multiple radionuclide classes, molecular targets, and care settings underscores the breadth of clinical and manufacturing infrastructure now supporting this category.

Executive Snapshot

How does PSMA-targeted prostate cancer treatment demand drive radioligand therapy market growth?

Oncology centers are increasingly administering PSMA-directed agents, including lutetium-177 vipivotide tetraxetan, for the treatment of metastatic castration-resistant prostate cancer, establishing this indication as the largest single contributor to market revenue. As diagnostic screening rates hold steady and treatment eligibility criteria continue to broaden, procurement associated with this indication is expected to outpace growth across the wider specialty pharmaceutical sector.

What role does neuroendocrine tumor application growth play in market growth?

Nuclear medicine departments are placing greater reliance on somatostatin receptor-targeted agents, such as lutetium-177 dotatate, in the management of gastroenteropancreatic neuroendocrine tumors. Improved diagnostic detection combined with expanding referral pathways into specialized treatment centers continues to support consistent demand growth within this indication.

How does alpha-emitter pipeline adoption sustain radioligand therapy market growth?

Biopharmaceutical developers continue to advance alpha-particle-emitting candidates based on actinium-225 and lead-212 chemistry, valued for their capacity to deliver concentrated, short-range cytotoxic effects to targeted tumor cells. Increased clinical trial investment directed toward these programs is generating demand that exceeds levels attributable to conventional beta-emitting agents alone.

What is driving demand for radioligand therapy in fibroblast activation protein-targeted applications?

Developers pursuing FAP-targeted candidates are extending radioligand therapy into tumor types beyond the established prostate cancer and neuroendocrine tumor indications. This broadening of eligible cancer types is generating incremental demand among clinical-stage biopharmaceutical developers pursuing larger addressable patient populations.

How does centralized radiopharmacy manufacturing demand sustain the radioligand therapy market?

Given the short half-life and specialized handling requirements associated with radioligand products, manufacturers continue to invest in centralized radiopharmacy networks and distribution infrastructure. As patient treatment volumes increase, this infrastructure investment is emerging as a growth driver of comparable significance to the therapeutic pipeline itself.

Which radioligand therapy market segments are growing fastest?

The fastest-growing segments include alpha-emitting products based on actinium-225 and lead-212 chemistry, earlier treatment-line applications supported by expanding clinical evidence, candidates approaching regulatory clearance, and specialized nuclear medicine centers expanding treatment capacity.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Radioligand Therapy Market

  • Prostate cancer sustaining the leading share of radioligand therapy revenue: Treatment of metastatic castration-resistant prostate cancer with PSMA-targeted agents continues to represent the largest single indication by procurement value across the category.
  • Neuroendocrine tumors and GEP-NETs sustaining a substantial secondary demand channel: Somatostatin receptor-directed therapy continues to gain traction among specialized nuclear medicine providers treating gastroenteropancreatic tumors.
  • Alpha-emitting agents sustaining demand growth above conventional beta-emitter chemistry: The concentrated cytotoxic profile associated with alpha-particle chemistry is directing incremental clinical and commercial investment away from conventional beta-emitting radioligands.
  • FAP-targeted and other emerging targets sustaining a broadening addressable tumor base: Candidates directed at fibroblast activation protein and related markers continue to extend radioligand therapy’s applicability beyond its historical core indications.
  • Late-stage and near-launch candidates sustaining anticipatory demand ahead of approval: As regulatory submissions progress, treatment centers and payers continue to prepare for an expanding set of newly approved therapeutic options.
  • Specialized nuclear medicine centers and academic cancer centers sustaining primary care delivery: Facilities equipped for radioligand handling and administration continue to serve as the principal point of care across this category.

Market Segmentation: Radioligand Therapy Market

By Product Type
  • Lutetium-177 Vipivotide Tetraxetan
  • Lutetium-177 Dotatate
  • Radium-223 Dichloride
  • Lu-177 PNT2002
  • Ac-225-PSMA-617
  • FPI-2265
  • I-131-1095
  • TLX591
  • AlphaMedix (²¹²Pb-DOTAMTATE)
  • ⁶⁷Cu-SAR-BisPSMA
  • Other Products
By Radionuclides
  • Lutetium-177 (Lu-177)
  • Actinium-225 (Ac-225)
  • Radium-223 (Ra-223)
  • Lead-212 (Pb-212)
  • Iodine-131 (I-131)
  • Copper-67 (Cu-67)
  • Other Radionuclides
By Indication
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • Breast Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Other Solid Tumors
  • Hematological Malignancies
  • Other Indications
By Target
  • Prostate-Specific Membrane Antigen (PSMA)
  • Somatostatin Receptor (SSTR)
  • Fibroblast Activation Protein (FAP)
  • Other Tumor-Associated Targets
By Radiation Type
  • Beta Emitters
  • Alpha Emitters
  • Auger Electron Emitters
  • Other Radiation Types
By Disease Stage
  • Locally Advanced Cancer
  • Metastatic Cancer
  • Advanced / Unresectable Cancer
  • Relapsed / Refractory Cancer
  • Treatment-Resistant Cancer
  • Others
By Route of Administration
  • Intravenous Administration
  • Intra-arterial Administration
  • Other Routes of Administration
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Distribution Channel
  • Direct Hospital / Cancer Center Supply
  • Specialty Radiopharmaceutical Distributors
  • Nuclear Medicine Distributors
  • Centralized Radiopharmacy Networks
  • Other Distribution Channels
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By Manufacturing Model
  • In-House Manufacturing
  • Contract Manufacturing
  • Centralized Radiopharmacy Manufacturing
  • Other Manufacturing Models
By End User
  • Tertiary Care Academic / Comprehensive Cancer Centers
  • Specialized Nuclear Medicine Centers
  • Hospitals
  • Specialty Oncology Centers
  • Academic & Research Institutes
  • Other End Users
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Radioligand Therapy Market

  1. Sustained prostate cancer incidence supporting continued PSMA-targeted therapy demand: Stable diagnosis rates combined with broadening treatment eligibility criteria continue to support procurement growth that exceeds the wider specialty pharmaceutical baseline.
  2. Expanding neuroendocrine tumor referral infrastructure supporting consistent therapy uptake: Improved diagnostic detection combined with growing specialized treatment center capacity continues to support demand for somatostatin receptor-targeted therapy.
  3. Increased clinical investment in alpha-emitting candidates reshaping competitive positioning: Growing confidence in the therapeutic potency of actinium-225 and lead-212 chemistry continues to direct research investment toward alpha-emitter development.
  4. Broadening tumor-type coverage through FAP-targeted research expanding the addressable market: As candidate development extends beyond prostate and neuroendocrine indications, the addressable patient population for radioligand therapy continues to expand.
  5. Rising patient treatment volumes supporting continued centralized radiopharmacy infrastructure investment: Short radionuclide half-lives and specialized handling requirements continue to drive manufacturer investment in dedicated production and distribution networks.
  6. Maturing regulatory pipelines supporting an approaching wave of commercial launches: A growing pipeline of late-stage candidates continues to focus treatment center and payer attention on the category’s next phase of expansion.

Regional Outlook: Radioligand Therapy Market

  • North America: The United States accounts for the largest share of regional demand, supported by prostate cancer and neuroendocrine tumor treatment volumes, broad payer coverage, and one of the most developed nuclear medicine treatment infrastructures globally; regional cancer centers continue to expand specialized capacity and radiopharmacy infrastructure to accommodate this demand.
  • Europe: Germany, France, and the United Kingdom anchor regional demand, supported by expanding specialized nuclear medicine center capacity and consistent clinical utilization across prostate cancer and neuroendocrine tumor care; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as treatment access expands for prostate cancer and neuroendocrine tumors; regional cancer centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized cancer centers begin to offer prostate cancer and neuroendocrine tumor radioligand treatment; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Radioligand Therapy Market

Key Players

Novartis AG, Bayer AG, Eli Lilly and Company, AstraZeneca plc, Bristol Myers Squibb Company, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Perspective Therapeutics, Inc., Clarity Pharmaceuticals Ltd., Curium Pharma, Orano Med, Ratio Therapeutics, Inc., POINT Biopharma (Eli Lilly and Company), Fusion Pharmaceuticals Inc. (AstraZeneca plc), RayzeBio, Inc. (Bristol Myers Squibb Company), Y-mAbs Therapeutics, Inc., Advanced Accelerator Applications (Novartis AG), Actinium Pharmaceuticals, Inc., Radiomedix, Inc., Isotopia Molecular Imaging Ltd.

Recent Developments

  • Novartis AG [March 2026] — confirmed continued expansion of its radioligand therapy manufacturing capacity supporting Pluvicto and Lutathera, with the company noting sustained global patient demand across prostate cancer and neuroendocrine tumor indications.
  • Eli Lilly and Company [December 2025] — reported continued clinical development of its PSMA-targeted radioligand pipeline following its acquisition of POINT Biopharma, with the company noting sustained physician interest in earlier treatment line applications.
  • AstraZeneca plc [September 2025] — confirmed continued clinical progress for its FAP-targeted and alpha-emitter radioligand pipeline following its acquisition of Fusion Pharmaceuticals, with the company reporting structured investor and partner interest in next-generation targeted radiotherapeutics.

Consultant POV

The Radioligand Therapy Market’s exceptional 14.2% CAGR, projected to take the market from USD 3.3 billion in 2025 to approximately USD 10.9 billion by 2035, is anchored in sustained PSMA-targeted prostate cancer treatment demand, growing neuroendocrine tumor application activity, and continued alpha-emitter pipeline advancement. Sustained clinical and manufacturing investment from companies including Novartis AG, Eli Lilly and Company, and AstraZeneca plc confirms the Radioligand Therapy Market will sustain exceptional growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report